Atlas Trials

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects

Clinical trial NCT07327697 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07327697
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy Participants
Start date
2025-12-22
Primary completion
2026-07-01
Enrollment
178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.